Cambridge, United States
Kernal Biologics, founded in 2016, is pioneering advancements in the Biotechnology, Health and Wellness, and Pharmaceutical sectors. Based in the United States, the company focuses on developing mRNA therapies that instruct specific cells to manufacture their own medicine, offering potential cures for severe diseases such as cancer.
Building upon expertise from prestigious institutions like MIT and Harvard, alongside significant industry experience from Big Pharma, the Kernal team has previously demonstrated success through a prior biotech venture. The company's scientific credentials and strategic focus align with current market trends, emphasizing innovative therapeutic approaches.
Their latest funding milestone came on 01 October 2025, when the Advanced Research Projects Agency for Health (ARPA-H) invested in the company via a grant. This backing not only underscores Kernal's strategic importance but also highlights its potential for substantial impact within the biotech landscape.
Nuntius Therapeutics